Generic Name and Formulations:
Clonidine HCl 0.1mg, 0.2mg; extended-release tablets.
Concordia Pharmaceuticals Inc.
Indications for KAPVAY:
Attention deficit hyperactivity disorder (ADHD).
<6yrs: not recommended. Swallow whole. Titrate by response. Initially 0.1mg at bedtime for 1 week, then 0.1mg twice daily for 1 week, then 0.1mg in the morning and 0.2mg at bedtime for 1 week, then 0.2mg twice daily. Withdraw gradually; reduce by 0.1mg/day at 3–7 day intervals. Renal dysfunction: may need reduced dose.
Hypotension, bradycardia, heart block, vascular disease, cardio- or cerebrovascular disease, chronic renal failure, conduction disturbances: uptitrate slowly and monitor. History of, or conditions that predispose to syncope. Monitor pulse, BP. Maintain adequate hydration. Reevaluate periodically. Pregnancy (Category C). Nursing mothers.
Potentiates alcohol, other CNS depressants, antihypertensives. Hypotensive effect may be antagonized by tricyclic antidepressants. Additive AV block, bradycardia with drugs that affect cardiac conduction (eg, digitalis, calcium channel blockers, β-blockers). Avoid other forms of clonidine. May need to adjust dose of concurrent stimulant medication.
Central alpha-2 agonist.
Somnolence, fatigue, upper respiratory tract infection, irritability, sore throat, insomnia, nightmares, emotional disorder, constipation, nasal congestion, fever, dry mouth, ear pain.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)